High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides

Journal of Investigative Dermatology

Volumn 132, Issue 3 PART 1, 2012, Pages 703-710

  Kadin, Marshall E ^a   Pavlov, Igor Y ^b   Delgado, Julio C ^b   Vonderheid, Eric C ^c  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CD40 LIGAND; CYTOKINE RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CYTOKINE RELEASE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MYCOSIS FUNGOIDES; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SKIN LYMPHOMA; TH2 CELL; TREATMENT RESPONSE;

EID: 84857045124     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.351     Document Type: Article

References (31)

1. Barzilai A, Trau H, David M et al. (2006) Mycosis fungoides associated with B-cell malignancies. Br J Dermatol 155:379-86 (Pubitemid 44050573)
2. Bekkenk MW, Geelen FA, van Voorst Vader PC et al. (2000) Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: A report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653-61 (Pubitemid 30412833)
3. Borchmann P (2008) CD30+ diseases: Anaplastic large-cell lymphoma and lymphomatoid papulosis. Cancer Treat Res 142:349-65
4. Braun FK, Hirsch B, Al-Yacoub N et al. (2010) Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP. J Invest Dermatol 130:826-40
5. Burg G, Dummer R, Haeffner A et al. (2001) From inflammation to neoplasia: Mycosis fungoides evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors. Arch Dermatol 137:949-52 (Pubitemid 32641658)
6. Burg G, Kempf W, Kazakov DV et al. (2003) Pyogenic lymphoma of the skin: A peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. Br J Dermatol 148:580-6 (Pubitemid 36461341)
7. Chechlinska M, Kowalewska M, Nowak R (2010) Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer 10:2-3
8. Del Prete G, De Carli M, Almerigogna F et al. (1995) Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 9:81-6
9. Edinger JT, Clark BZ, Pucevich BE et al. (2009) CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol 33:1860-8
10. El Shabrawi-Caelen L, Kerl H, Cerroni L (2004) Lymphomatoid papulosis: Reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol 140:441-7 (Pubitemid 38469247)
11. Gause A, Jung W, Schmits R et al. (1992) Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma. Ann Oncol 3(Suppl 4):49-52
12. Gruber R, Sepp NT, Fritsch PO et al. (2006) Prognosis of lymphomatoid papulosis. Oncologist 11:955-7; author reply 7
13. Hallermann C, Kaune KM, Tiemann M et al. (2007) High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol 86:509-15
14. Herro E, Dicaudo DJ, Davis MD et al. (2009) Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic. J Am Acad Dermatol 61:271-5
15. Izban KF, Ergin M, Qin J et al. (2000) Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: Implications for apoptosis resistance and pathogenesis. Hum Pathol 31:1482-90 (Pubitemid 32047000)
16. Kadin ME (2000) Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol 156:1479-84 (Pubitemid 30646686)
17. Kadin ME (2006) Pathobiology of CD30+ cutaneous T-cell lymphomas. J Cutan Pathol 33(Suppl 1):10-7
18. Kim YH, Jensen RA, Watanabe GL et al. (1996) Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132:1309-13 (Pubitemid 26386618)
19. Levi E, Wang Z, Petrogiannis-Haliotis T et al. (2000) Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: A possible mechanism for disease progression. J Invest Dermatol 115:1034-40 (Pubitemid 32037448)
20. Li S, Ross DT, Kadin ME et al. (2001) Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray. Am J Pathol 158:1231-7 (Pubitemid 32281286)
21. Nadali G, Vinante F, Ambrosetti A et al. (1994) Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 12:793-7 (Pubitemid 24110920)
22. Pavlov I, Martins TB, Delgado JC (2009) Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing. Clin Vaccine Immunol 16:1327-31
23. Purdue MP, Lan Q, Martinez-Maza O et al. (2009) A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood 114:2730-2
24. Siebert S, Amos N, Williams BD et al. (2007) Cytokine production by hepatic anaplastic large-cell lymphoma presenting as a rheumatic syndrome. Semin Arthritis Rheum 37:63-7 (Pubitemid 47087886)
25. Stein H, Mason DY, Gerdes J et al. (1985) The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-58 (Pubitemid 15242469)
26. van Doorn R, Van Haselen CW, van Voorst Vader PC et al. (2000) Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 136:504-10 (Pubitemid 30212962)
27. Vendrame E, Martinez-Maza O (2011) Assessment of pre-diagnosis biomarkers of immune activation and inflammation: Insights on the etiology of lymphoma. J Proteome Res 10:113-9
28. Wasik MA, Vonderheid EC, Bigler RD et al. (1996) Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 132:42-7 (Pubitemid 26024809)
29. Willemze R, Beljaards RC (1993) Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 28:973-80 (Pubitemid 23160651)
30. Willemze R, Jaffe ES, Burg G et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-85 (Pubitemid 40656118)
31. Zinzani PL, Pileri S, Bendandi M et al. (1998) Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 16:1532-7 (Pubitemid 28175777)